Cargando…

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

AIMS/HYPOTHESIS: After coronary artery bypass graft (CABG) surgery in individuals with type 2 diabetes, there remains a considerable residual cardiovascular risk. In the EMPA-REG OUTCOME® trial in participants with type 2 diabetes and established cardiovascular disease, empagliflozin reduced the ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Subodh, Mazer, C. David, Fitchett, David, Inzucchi, Silvio E., Pfarr, Egon, George, Jyothis T., Zinman, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061159/
https://www.ncbi.nlm.nih.gov/pubmed/29777264
http://dx.doi.org/10.1007/s00125-018-4644-9
_version_ 1783342163947421696
author Verma, Subodh
Mazer, C. David
Fitchett, David
Inzucchi, Silvio E.
Pfarr, Egon
George, Jyothis T.
Zinman, Bernard
author_facet Verma, Subodh
Mazer, C. David
Fitchett, David
Inzucchi, Silvio E.
Pfarr, Egon
George, Jyothis T.
Zinman, Bernard
author_sort Verma, Subodh
collection PubMed
description AIMS/HYPOTHESIS: After coronary artery bypass graft (CABG) surgery in individuals with type 2 diabetes, there remains a considerable residual cardiovascular risk. In the EMPA-REG OUTCOME® trial in participants with type 2 diabetes and established cardiovascular disease, empagliflozin reduced the risk of cardiovascular death by 38%, all-cause mortality by 32%, hospitalisation for heart failure by 35% and incident or worsening nephropathy by 39% vs placebo when given in addition to standard of care. The aim of this post hoc analysis of the EMPA-REG OUTCOME® trial was to determine the effects of the sodium glucose cotransporter 2 inhibitor empagliflozin on cardiovascular events and mortality in participants with type 2 diabetes and a self-reported history of CABG surgery. METHODS: The EMPA-REG OUTCOME® trial was a randomised, double-blind, placebo-controlled trial. Participants with type 2 diabetes and established cardiovascular disease were randomised 1:1:1 to receive placebo, empagliflozin 10 mg or empagliflozin 25 mg, once daily, in addition to standard of care. In subgroups by self-reported history of CABG (yes/no) at baseline, we assessed: cardiovascular death; all-cause mortality; hospitalisation for heart failure; and incident or worsening nephropathy (progression to macroalbuminuria, doubling of serum creatinine, initiation of renal replacement therapy or death due to renal disease). Differences in risk between empagliflozin and placebo were assessed using a Cox proportional hazards model. RESULTS: At baseline, 25% (1175/4687) of participants who received empagliflozin and 24% (563/2333) of participants who received placebo had a history of CABG surgery. In participants with a history of CABG surgery, HRs (95% CI) with empagliflozin vs placebo were 0.52 (0.32, 0.84) for cardiovascular mortality, 0.57 (0.39, 0.83) for all-cause mortality, 0.50 (0.32, 0.77) for hospitalisation for heart failure and 0.65 (0.50, 0.84) for incident or worsening nephropathy. Results were consistent between participants with and without a history of CABG surgery (p > 0.05 for treatment by subgroup interactions). CONCLUSIONS/INTERPRETATION: In participants with type 2 diabetes and a self-reported history of CABG surgery, treatment with empagliflozin was associated with profound reductions in cardiovascular and all-cause mortality, hospitalisation for heart failure, and incident or worsening nephropathy. These data have important implications for the secondary prevention of cardiovascular events after CABG in individuals with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT01131676 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-018-4644-9) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
format Online
Article
Text
id pubmed-6061159
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-60611592018-08-09 Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial Verma, Subodh Mazer, C. David Fitchett, David Inzucchi, Silvio E. Pfarr, Egon George, Jyothis T. Zinman, Bernard Diabetologia Article AIMS/HYPOTHESIS: After coronary artery bypass graft (CABG) surgery in individuals with type 2 diabetes, there remains a considerable residual cardiovascular risk. In the EMPA-REG OUTCOME® trial in participants with type 2 diabetes and established cardiovascular disease, empagliflozin reduced the risk of cardiovascular death by 38%, all-cause mortality by 32%, hospitalisation for heart failure by 35% and incident or worsening nephropathy by 39% vs placebo when given in addition to standard of care. The aim of this post hoc analysis of the EMPA-REG OUTCOME® trial was to determine the effects of the sodium glucose cotransporter 2 inhibitor empagliflozin on cardiovascular events and mortality in participants with type 2 diabetes and a self-reported history of CABG surgery. METHODS: The EMPA-REG OUTCOME® trial was a randomised, double-blind, placebo-controlled trial. Participants with type 2 diabetes and established cardiovascular disease were randomised 1:1:1 to receive placebo, empagliflozin 10 mg or empagliflozin 25 mg, once daily, in addition to standard of care. In subgroups by self-reported history of CABG (yes/no) at baseline, we assessed: cardiovascular death; all-cause mortality; hospitalisation for heart failure; and incident or worsening nephropathy (progression to macroalbuminuria, doubling of serum creatinine, initiation of renal replacement therapy or death due to renal disease). Differences in risk between empagliflozin and placebo were assessed using a Cox proportional hazards model. RESULTS: At baseline, 25% (1175/4687) of participants who received empagliflozin and 24% (563/2333) of participants who received placebo had a history of CABG surgery. In participants with a history of CABG surgery, HRs (95% CI) with empagliflozin vs placebo were 0.52 (0.32, 0.84) for cardiovascular mortality, 0.57 (0.39, 0.83) for all-cause mortality, 0.50 (0.32, 0.77) for hospitalisation for heart failure and 0.65 (0.50, 0.84) for incident or worsening nephropathy. Results were consistent between participants with and without a history of CABG surgery (p > 0.05 for treatment by subgroup interactions). CONCLUSIONS/INTERPRETATION: In participants with type 2 diabetes and a self-reported history of CABG surgery, treatment with empagliflozin was associated with profound reductions in cardiovascular and all-cause mortality, hospitalisation for heart failure, and incident or worsening nephropathy. These data have important implications for the secondary prevention of cardiovascular events after CABG in individuals with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT01131676 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-018-4644-9) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2018-05-19 2018 /pmc/articles/PMC6061159/ /pubmed/29777264 http://dx.doi.org/10.1007/s00125-018-4644-9 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Verma, Subodh
Mazer, C. David
Fitchett, David
Inzucchi, Silvio E.
Pfarr, Egon
George, Jyothis T.
Zinman, Bernard
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
title Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
title_full Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
title_fullStr Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
title_full_unstemmed Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
title_short Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
title_sort empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the empa-reg outcome® randomised trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061159/
https://www.ncbi.nlm.nih.gov/pubmed/29777264
http://dx.doi.org/10.1007/s00125-018-4644-9
work_keys_str_mv AT vermasubodh empagliflozinreducescardiovasculareventsmortalityandrenaleventsinparticipantswithtype2diabetesaftercoronaryarterybypassgraftsurgerysubanalysisoftheemparegoutcomerandomisedtrial
AT mazercdavid empagliflozinreducescardiovasculareventsmortalityandrenaleventsinparticipantswithtype2diabetesaftercoronaryarterybypassgraftsurgerysubanalysisoftheemparegoutcomerandomisedtrial
AT fitchettdavid empagliflozinreducescardiovasculareventsmortalityandrenaleventsinparticipantswithtype2diabetesaftercoronaryarterybypassgraftsurgerysubanalysisoftheemparegoutcomerandomisedtrial
AT inzucchisilvioe empagliflozinreducescardiovasculareventsmortalityandrenaleventsinparticipantswithtype2diabetesaftercoronaryarterybypassgraftsurgerysubanalysisoftheemparegoutcomerandomisedtrial
AT pfarregon empagliflozinreducescardiovasculareventsmortalityandrenaleventsinparticipantswithtype2diabetesaftercoronaryarterybypassgraftsurgerysubanalysisoftheemparegoutcomerandomisedtrial
AT georgejyothist empagliflozinreducescardiovasculareventsmortalityandrenaleventsinparticipantswithtype2diabetesaftercoronaryarterybypassgraftsurgerysubanalysisoftheemparegoutcomerandomisedtrial
AT zinmanbernard empagliflozinreducescardiovasculareventsmortalityandrenaleventsinparticipantswithtype2diabetesaftercoronaryarterybypassgraftsurgerysubanalysisoftheemparegoutcomerandomisedtrial